Literature DB >> 23669749

Significance of rebounding parathyroid hormone levels during parathyroidectomy.

David F Schneider1, Kristin A Ojomo, Haggi Mazeh, Sarah C Oltmann, Rebecca S Sippel, Herbert Chen.   

Abstract

BACKGROUND: Using minimally invasive parathyroidectomy (MIP), most surgeons require a 50% decline in intraoperative parathyroid hormone (IoPTH) to determine cure, but the significance of IoPTH kinetics occurring after this drop remains unknown. The aim of this study was to determine the impact of IoPTH levels that first meet criteria for cure, but then increase again, or rebound, between 10 and 15 min postexcision.
METHODS: We conducted a retrospective review of patients undergoing initial parathyroidectomy for primary hyperparathyroidism at our institution from 2001 to 2011. Rebound IoPTH was defined as an increase in parathyroid hormone ≥5 pg/mL after achieving the 50% drop required for cure. Comparisons were evaluated with the Student t-test, chi-square test, or Fisher exact test where appropriate.
RESULTS: Of the 1386 patients who met selection criteria, 86 (6.2%) patients exhibited rebound IoPTH. The mean magnitude of rebound was 13.8 ± 3.6 pg/mL. Compared with those not displaying rebound, more patients with rebound IoPTH were treated with open parathyroidectomy rather than MIP (10.8% versus 4.5%, P < 0.01). The recurrence rate among those with rebound IoPTH was more than double that of the patients without rebound IoPTH (5.8% versus 2.2%, P = 0.03). Magnitude of rebound, however, did not correlate with recurrence. The rate of persistent disease was not different between those with and without rebound IoPTH. Rebound was a much better indicator of recurrence than patients whose final IoPTH levels were not within the normal range.
CONCLUSIONS: Rebound IoPTH is more common in patients who develop recurrent hyperparathyroidism. Therefore, surgeons should closely monitor patients with rebound IoPTH for disease recurrence.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intraoperative parathyroid hormone monitoring; Minimally invasive parathyroidectomy; Primary hyperparathyroidism; Recurrence

Mesh:

Substances:

Year:  2013        PMID: 23669749      PMCID: PMC3748171          DOI: 10.1016/j.jss.2013.04.024

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  25 in total

1.  Six hundred fifty-six consecutive explorations for primary hyperparathyroidism.

Authors:  Robert Udelsman
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

2.  Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy.

Authors:  Herbert Chen; Zachary Pruhs; James R Starling; Eberhard Mack
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

3.  Interpretation of intraoperative parathyroid hormone monitoring in patients with baseline parathyroid hormone levels of <100 pg/mL.

Authors:  Barbra S Miller; Barry G England; Matthew Nehs; Richard E Burney; Gerard M Doherty; Paul G Gauger
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

4.  Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease.

Authors:  A Bergenfelz; S Valdemarsson; S Tibblin
Journal:  Surgery       Date:  1996-06       Impact factor: 3.982

5.  Persistently elevated parathyroid hormone levels after parathyroid surgery.

Authors:  Tracy S Wang; Samuel T Ostrower; Keith S Heller
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

6.  A new approach to parathyroidectomy.

Authors:  G L Irvin; D L Prudhomme; G T Deriso; G Sfakianakis; S K Chandarlapaty
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

7.  Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases.

Authors:  David F Schneider; Haggi Mazeh; Rebecca S Sippel; Herbert Chen
Journal:  Surgery       Date:  2012-10-12       Impact factor: 3.982

8.  Primary hyperparathyroidism: intraoperative PTH-measurements.

Authors:  L Rolighed; L Heickendorff; I Hessov; J P Garne; S A Rodt; P Christiansen
Journal:  Scand J Surg       Date:  2004       Impact factor: 2.360

9.  Value of intraoperative parathyroid hormone monitoring.

Authors:  Jyotirmay Sharma; Mira Milas; Eren Berber; Peter Mazzaglia; Alan Siperstein; Collin J Weber
Journal:  Ann Surg Oncol       Date:  2007-11-17       Impact factor: 5.344

10.  Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT).

Authors:  Giorgos Constantine Karakousis; Dale Han; Rachel Rapaport Kelz; Deepika Nemani; Jagajan Karamacharya; Robert Roses; Phyllis A Gimotty; Douglas L Fraker
Journal:  Surgery       Date:  2007-12       Impact factor: 3.982

View more
  2 in total

1.  What Should We Tell Our Patients? Lifetime Guarantee or is it 5- to 10-year Warranty on a Parathyroidectomy for Primary Hyperparathyroidism?

Authors:  Janice L Pasieka
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

2.  Justified follow-up: a final intraoperative parathyroid hormone (ioPTH) Over 40 pg/mL is associated with an increased risk of persistence and recurrence in primary hyperparathyroidism.

Authors:  Mohammad H Rajaei; Alex M Bentz; David F Schneider; Rebecca S Sippel; Herbert Chen; Sarah C Oltmann
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.